Free Trial
TSE:SVA

Sernova Q3 2023 Earnings Report

Sernova logo
C$0.20 0.00 (0.00%)
As of 08/8/2025 03:59 PM Eastern

Sernova EPS Results

Actual EPS
-C$0.03
Consensus EPS
-C$0.02
Beat/Miss
Missed by -C$0.01
One Year Ago EPS
N/A

Sernova Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sernova Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Monday, September 11, 2023
Conference Call Time
6:00PM ET

Earnings Documents

Sernova Earnings Headlines

Sernova Biotherapeutics Inc (SVA.TO) - Yahoo Finance Canada
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
SVA:CA Sernova Biotherapeutics Inc - Seeking Alpha
Stocks in play: Sernova Biotherapeutics
Sernova Biotherapeutics Inc SVA
See More Sernova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova and other key companies, straight to your email.

About Sernova

Sernova (TSE:SVA) Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on Type 1 diabetes and thyroid disorders.

View Sernova Profile

More Earnings Resources from MarketBeat